Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 6 » default

ESCI
Impact Factor

Blood and Lymphatic Cancer: Targets and Therapy

ISSN: 1179-9889


       

Archive: Volume 6, 2016

Review

Waldenström macroglobulinemia: biology, genetics, and therapy

Paludo J, Ansell SM

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:49-58

Published Date: 26 July 2016

Review

Managing treatment-related peripheral neuropathy in patients with multiple myeloma

Grammatico S, Cesini L, Petrucci MT

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:37-47

Published Date: 29 June 2016

Review

Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes

Faiman B, Valent J

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:21-35

Published Date: 24 May 2016

Review

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

Vaddi K, Verstovsek S, Kiladjian JJ

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:7-19

Published Date: 12 May 2016

Review

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Madanat YF, Smith MR, Almasan A, Hill BT

Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:1-6

Published Date: 15 March 2016